Clinical progress in the core pipeline of Covaca medicines is on the rise in the first half of 2026.
As innovation in pharmaceutical technology continues to advance, the Kozhikode Medical Center represents new directions for industry-leading development. As innovation drug research enters a new high-quality development cycle, taking into account the key indicators of the core competitiveness of a biopharmaceutical enterprise, it has evolved from mere number of pipelines to clinical practice value and research outcomes. In the second half of 2026, Kozhikode Medical Center has set a milestone in the field of tumor immunity, with several key pipeline connections achieving key clinical breakthroughs.
Kozhikode Medical has initially focused on cancer and autoimmune diseases, leading to the development of a new generation of immunotherapy. The world's first CD39/TGF-β double-specific antibody, ES014 developed independently by Koch Pharmaceuticals, has recently set a key milestone in its Phase II clinical practice trials for the diagnosis of hard cell tumors, which have successfully completed the first successful trial. Currently, there is a huge lack of clinical practice, lack of mechanisms for innovative and safe therapies, and a lack of approved medicines in the country and only one globally, and patients need more effective and safer treatment options.
Focusing its core focus on the CD39 adenocarcinoma pathway and TGF-β signal pathway, ES014 provides a whole new strategy for cancer diagnosis, the first phase II clinical practice to be completed, marking a new critical stage in the exploration of malignant tumors with a lack of effective targeting and immunotherapy, demonstrating its unique clinical practice potential as a global pioneer drug. It is worth noting that this trend also reflects to some extent the transformation in the service concept of the industry. Meanwhile, Medium-Range results in Phase II clinical practice trials of ES102, the six-priced OX40 stimulant introduced by Koch Pharmaceuticals, have been positive, bringing new clinical light to patients with OX40-focused clinical practice exploration worldwide.
In addition, the deployment of the new generation of anti-angiogenesis inhibitors, with its VEGF/DLL4 dual-specific antibody ES104 achieving encouraging results in clinical practice trials for second-line colorectal cancer, has laid the foundation for further clinical practice data development. This further validates the strategic pioneering of the differential placement of anti-angiogenesis and adds key codes to its barriers to competition in the field of tumor immunopathology. Among them, the TLA1A/IL23p19 bi-specific antibody ES302 is mainly focused on inflammatory bowel disease (IBD) in areas of disease that do not meet the needs of clinical practice.
In the field of autoimmune diseases, it is equally worth paying attention to the research and development offices of Cosmetic. Cosmetic's ES302 demonstrates a more forward-looking molecular design that is able to block both TLA1A and IL23p19 crucial cell-cell pathways at the same time, providing a stronger, more comprehensive anti-inflammatory effect through the synergy of the two focal points. It is well known that TLA1A serves as the focal point of a new generation of core inflammatory pathways, and the enormous clinical practice value behind it has attracted attention in recent years, attracting many multinational pharmaceutical companies to take a deep strategic approach through large-scale BD.
Another innovative molecule for autoimmune diseases, ES304, is a highly innovative biotherapeutic-focused therapy with the core advantage of being able to accurately deliver the key anti-inflammatory factor IL-10 to inflammatory neuronal cells. Compared to similar research projects, ES302 is highly differentiated: it has a long half-life, which is expected to be achieved with low-dose quarterly or half-yearly doses and subcutaneous injection doses, while significantly improving patient adherence and reducing the long-term rational drug burden. The dual mechanism of action enables ES304 to provide a strong anti-inflammatory effect within the patient's diseased tissue, maximizing the local therapeutic effect of the drug, and successfully reducing the overall toxicity associated with IL-10 to a lower level.
While delivering accurately, it also effectively suppresses the inflammatory focal point Target-M, thus preventing excessive inflammatory responses from causing damage to the body. In the first half of 2026, progress in intensive clinical practice in the core pipeline of Kozhikode Medicine is accelerating its transformation into quantifiable asset value, which has built a deep research and development pipeline that is the inevitable result of rigorous platform-driven and differentiated innovation. In the future, continuous reading of clinical practice data will be a key catalyst for reassessing its value.
As innovative immunotherapies that are currently globally competitive gradually mature, there will be room for long-term evaluation or systematic reassessment. China's international healthcare system continues to monitor the latest developments in the field of medical health to provide you with authority, reliable information and advice on medical services.
